卡左双多巴控释片对帕金森病伴发抑郁患者的效果

The effect of Kazuo double dopa controlled release tablets in the Parkinson’s disease patients with depression

目的评价卡左双多巴控释片治疗帕金森病伴发抑郁的临床效果。方法以不同的治疗方案作为分组依据,将2017年10月~2019年6月本院收治的66例帕金森病伴发抑郁的患者分为对照组、观察组各33例。对照组用常规治疗,观察组用卡左双多巴控释片治疗,对比两组的治疗有效率、抑郁症评分、生存质量评分和不良反应。结果治疗后观察组的治疗总有效率、生存质量评分高于对照组(P<0.05);观察组抑郁症评分低于对照组(P<0.05)。两组不良反应发生率没有明显差异(P>0.05)。结论卡左双多巴控释片不仅可以改善帕金森病伴发抑郁患者的抑郁症状,还可提高生存质量。

Objective To evaluate the clinical effect of Kazuo Double Dopa Controlled Release Tablets in the treatment of Parkinson’s disease patients with depression. Methods Sixty-six Parkinson’s disease patients with depression were enrolled in the hospital from October 2017 to June 1919. The clinical data were reviewed and different treatment plans were used as a group basis.66 patients were divided into two groups,33 cases in the each group. The control group was treated with conventional therapy. Based on this,the observation group was treated with Kazuo double dopa controlled release tablets,and the total effective rate,depression score,quality of life score,and adverse reaction were compared between two groups. Results The total effective rate and quality of life scores in the observation group was higher than those in the control group(P<0.05);the depression score in the observation group was lower than that in the control group,(P< 0.05). There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05). Conclusion Cardo-dual dopa controlled release tablets for the treatment of Parkinson’s disease patients with depression can not only improve the patient’s depressive symptoms,but also improve the quality of life.